Mitchell B. Sheinkop, M.D.

01/30/2024

NEW PROVIDER RECOMMENDATION

SCHROEDER MD REGENERATIVE ORTHOPEDICS

KEITH E. SCHROEDER, MD // ORTHOPEDIC SPECIALIST

Dr. Sheinkop highly recommends Schroeder MD Regenerative Orthopedics, founded by Dr. Keith E. Schroeder, for all your non-invasive Orthopedic needs.

Dr. Schroeder established Barrington Orthopedic Specialists in 1980 and grew the practice to what it is today, offering an impressive roster of orthopedic surgeons, podiatric surgeons, and physical medicine and rehabilitation specialists all committed to providing exceptional care throughout the northwest suburbs.

After spending more than 40 years as an orthopedic surgeon, Dr. Schroeder is now specializing in the orthopedic area of regenerative medicine and launched Schroeder MD Regenerative Orthopedics (SRO) to help patients avoid or postpone surgery via cellular-based treatments. His philosophy has always been to help patients achieve the best possible outcomes.

Specializing in the treatment of osteoarthritis, sports and activity-related joint pain and discomfort with cellular-based treatments, SRO offers:

-Bone Marrow Concentrate (Mesenchymal Stem Cell Therapy)

-Platelet-rich Plasma (PRP)

-Adipose therapy (M-Fat)

-General Orthopedic Therapies

Treatment is offered for:

Knees
Hips
Shoulders
Elbows
Ankles
Wrists

Now scheduling self-pay appointments to begin on January 16, 2024. Call (847) 989-1399 to schedule today.

Hours:
Tuesday 8a-3p
Wednesday 10a-4:30p

Schroeder MD Regenerative Orthopedics
1110 W. Schick Rd.
Bartlett, IL 60103
(847)989-1399

09/19/2023

"When you are finished changing, you are finished” is a quote attributed to Benjamin Franklin. For 39 years, I was a joint replacement surgeon at a large academic medical center in Chicago where I rose to be the Head of the Joint Replacement Program and Professor of Orthopedic Surgery. My next stop for 11 years has been in the emerging discipline of Regenerative Medicine. In the latter, I introduced evidence-based medicine integrating clinical practice with clinical research. In so doing, I worked with several biotech companies proving outcomes data by continually monitoring the results of my care and treatment. Now, it is time to graduate into yet another initiative; namely, as both a consultant and director of medical affairs within the field of regenerative medicine and cellular orthopedics.

Continuing the Climb
On July 31, 2023 I retired from clinical practice. The mission has been to assist the patient in postponing, at times avoiding, a joint replacement. It has been my pleasure to care for and successfully treat my patients. For medical records please contact my office (312)475-1893.

08/08/2023

On July 31, 2023, Mitchell Sheinkop, MD retired from clinical practice. He will still be involved in monitoring patient outcomes of the Platelet Rich Plasma, Bone Marrow Concentrate, and Micro Fractured Adipose. If you are a Patient who has been recently treated by Mitchell Sheinkop, MD, our offices will be contacting you via phone or email.



Office staff will be available to you until December 31, 2023 (312) 475-1893 should you have questions or need assistance with medical records requests.



For 39 years, Mitchell Sheinkop, MD was a joint replacement surgeon at a large academic medical center in Chicago where he rose to be the Head of the Joint Replacement Program and Professor of Orthopedic Surgery.

His next stop for the past 11 years has been in the emerging discipline of Regenerative Medicine. He continued evidence-based medicine integrating clinical practice with clinical research into the regenerative realm. In so doing, he worked with several biotech companies proving outcomes data by continually monitoring the results of his care and treatment.

Now, it is time to graduate into yet another initiative; namely, as both a consultant and director of medical affairs within the field of regenerative medicine and cellular orthopedics.



The impact that he has made both caring for his Patients and advancing the field of Orthopedic/ Regenerative Medicine has been insurmountable.



Please feel free to send your congratulations & well wishes for Mitchell Sheinkop, MD to:

Phone or text: (312) 475-1893

Fax (312) 910-2460

Email: kelly@sheinkopmd.com

USPS: 1332 N Halsted St STE 101, Chicago, IL 60642



It has been a pleasure caring for You and Your Family!



Kindly,

The Staff of Mitchell B. Sheinkop, M.D.

03/13/2023

It has been many years since I took personal time off to change offices and receive a “tune up” for my arthritic joint right hip. I am back. This past Wednesday, I completed three concentrated bone marrow procedures in my new settings under local anesthesia in our specially designed treatment room.

READ MORE:

It's been many years since I took personal time off to change offices and receive a “tune up” for my arthritic joint right hip. I am back.

01/06/2023

Looking forward in 2023, our first clinical day in the new offices at 618 West Fulton Street, Chicago, Illinois 60661 is Tuesday, January 10.

Exciting new developments shared on this new clinical study:

Dr. Sheinkop's clinical study with micro-fractured fat to depress inflammation, sending bodily signals to regenerate healthy tissue and heal.

12/12/2022

Our Chicago office will move to 618 West Fulton, 60661 as of January 1, 2023. We will be able to offer several “bedside” possibilities in my new office, in a specialized treatment room.

To schedule your consultation, call (847) 390-7666 until December 31, 2023; after that, please call (312) 475-1893.

CONTINUE READING:

Dr. Sheinkop's patient outcomes database contains follow-up of 285 hips and 802 knees that have been comprehensively monitored for 7+ years.

10/17/2022

At this point in time, Personalized Stem Cells (PSC) is still planning to submit a request for the second phase Clinical Trial to the FDA anticipating that the FDA will ultimately take issue with the California Appellate Court decision.

READ MORE:

Discussing the possibility of a second Adipose Based Stem Cell Clinical Trial sponsored by PSC; first trial was completed over 18 months ago.

10/03/2022

In the scientific publication cited here, 8.6% of the population studied did not meet the recognized inclusion criteria for a Total Joint Replacement. Gain insight from Dr. Sheinkop in his review and commentary on this study.

READ MORE:

What other options are there when it isn't time for joint replacement surgery? This post explains various minimally invasive solutions.